Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.
The OTC industry could convince Mississippi lawmakers to allow nonprescription, behind-the-counter sales of some pseudoephedrine-containing drugs if it shows electronic sales tracking is a less burdensome way to curb purchases of the ingredient used to make methamphetamine, says former governor Haley Barbour.
At the Consumer Healthcare Products Association’s Annual Executive Conference March 10, Barbour said “it is worth it” for the industry...
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.
